Corza Medical, a new venture backed by the financial firepower of private equity giant GTCR, is looking to build a surgical tool supplier that its executive chairman Greg Lucier says can compete with “almost monopolistic” leaders in the space.
To mount the challenge, Corza acquired Surgical Specialties Corp., a supplier of surgical sutures and ophthalmic knives. Corza will use this beachhead in Westwood, Mass., to build a pipeline of acquired assets including TachoSil, a surgical patch product line Corza acquired from Takeda Pharmaceuticals last year.
In an interview with the DeviceTalks Weekly podcast, Lucier, the former CEO of spinal company NuVasive (NSDQ:NUVA) and diagnostic company Life Technologies, said management believes “there is an opening for a pretty good-sized surgical tools and technologies company to compete against the Ethicons and the Medtronics of the world.”
Lucier said the two Goliaths have reached a size that makes them “almost monopolistic with their bundling. Customers are looking for a choice where they can get that exceptional value with remarkable service. That’s what we’re going to do with Corza Medical.”
The interview will run in the upcoming podcast episode this Friday, Feb. 5, 2021.
You can read the rest of this article on our sister site, MassDevice.
